First and only GLP-1 pill on the market costs significantly less than injectable versions
The first pill version of the blockbuster GLP-1 weight loss drugs has been launched in the US by Novo Nordisk at a lower cost than jab varieties, accelerating a price war in the sector.
The Danish pharmaceutical company said on Monday that its once-a-day Wegovy pill, which received approval from the US regulator just before Christmas, was now available in the country.
It launched the drug – the first and only pill on the market that imitates the GLP-1 hormone to reduce appetite – at significantly lower prices than injectable versions.
Novo, which is known for its hit Wegovy and Ozempic injections for obesity and diabetes respectively, said the launch “opens new possibilities for the more than 100 million Americans living with obesity”.
